Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility

被引：0
作者：
Richard Lawson
Frederic King
Kevin Marsh
Arman Altincatal
Ali Cimen
机构：
[1] AstraZeneca,
[2] AstraZeneca,undefined
[3] Melbourn Science Park,undefined
[4] Evidera,undefined
[5] Evidera,undefined
来源：
Advances in Therapy | 2016年 / 33卷
关键词：
Constipation; Gastroenterology; EQ-5D; Health related quality of life; Laxative inadequate responder (LIR); Naloxegol; OIC; Opioid-induced constipation; Pain; Utility;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1331 / 1346
页数：15
相关论文
共 176 条
[41]  
Clark AJ(2006)Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden Acta Ophthalmol Scand 84 363-undefined
[42]  
Speechley M(2005)Development and validation of the patient assessment of constipation quality of life questionnaire Scand J Gastroenterol 40 540-undefined
[43]  
Morley-Forster PK(undefined)undefined undefined undefined undefined-undefined
[44]  
Mancini I(undefined)undefined undefined undefined undefined-undefined
[45]  
Bruera E(undefined)undefined undefined undefined undefined-undefined
[46]  
Bell TJ(undefined)undefined undefined undefined undefined-undefined
[47]  
Panchal SJ(undefined)undefined undefined undefined undefined-undefined
[48]  
Miaskowski C(undefined)undefined undefined undefined undefined-undefined
[49]  
Bolge SC(undefined)undefined undefined undefined undefined-undefined
[50]  
Milanova T(undefined)undefined undefined undefined undefined-undefined
12345678910